Literature DB >> 34972698

Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review.

Dragos Serban1,2, Daniel Ovidiu Costea3,4, Anca Zgura5,6, Mihail Silviu Tudosie7,8, Ana Maria Dascalu9,10, Gabriel Andrei Gangura1,11, Catalin Gabriel Smarandache1,2, Alexandru Dan Sabau12,13, Corneliu Tudor2, Mihai Faur12,13, Andreea Cristina Costea14, Daniela Stana10, Simona Andreea Balasescu2, Laura Carina Tribus15,16, Ciprian Tanasescu12,13.   

Abstract

BACKGROUND: Aromatase inhibitor therapy is currently the preferred choice in postmenopausal women with estrogen receptor positive breast cancer. This article reviews the ocular side effects of treatment with aromatase inhibitors (AIs) in patients with breast cancer.
MATERIALS AND METHODS: A comprehensive search was performed on PubMed, Web of Science and Google scholar.
RESULTS: After duplication removal, 14 clinical studies and 5 case reports, published between 2008 and 2021, were identified. Most frequently, AI treatment resulted in minor to moderate dry eye symptoms. "De novo" onset of Sjogren syndrome during AI therapy was also reported. Retinal and optic nerve side effects varied from mild, subclinical anatomic and functional impairment to severe decreased vision, secondary to hemi-central retinal artery occlusion, bilateral optic neuritis or uveitis with bilateral macular edema.
CONCLUSION: Visual disturbances encountered during AI treatment may be underestimated. Ophthalmic screening is important for early detection and appropriate treatment.
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Breast cancer; anastrozole; aromatase inhibitors; dry eye; endocrine therapy; ocular side-effects; review

Mesh:

Substances:

Year:  2022        PMID: 34972698      PMCID: PMC8765131          DOI: 10.21873/invivo.12674

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  50 in total

1.  Exemestane-induced corneal epithelial changes.

Authors:  Miltiadis Papathanassiou; Eleni Nikita; Panagiotis Theodossiadis; George P Theodossiadis; Ioannis Vergados
Journal:  Cutan Ocul Toxicol       Date:  2010-09       Impact factor: 1.820

2.  Bilateral Optic Disc Swelling Following Anastrozole Therapy.

Authors:  Oscar Jim Michael Coppes; Rimas V Lukas; Gini F Fleming; Jeffrey Nichols; Meaghan Tenney; Jacqueline Bernard
Journal:  Neuroophthalmology       Date:  2014-09-19

3.  Hormone replacement therapy and dry eye syndrome.

Authors:  D A Schaumberg; J E Buring; D A Sullivan; M R Dana
Journal:  JAMA       Date:  2001-11-07       Impact factor: 56.272

4.  Macular oedema due to letrozole: a first case report.

Authors:  Marilita M Moschos; Irini P Chatziralli; Flora Zagouri; George C Zografos
Journal:  Clin Exp Optom       Date:  2012-08-13       Impact factor: 2.742

5.  The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer.

Authors:  Tolga Bicer; Goksen Inanc Imamoglu; Aysun Sanal Dogan; Nese Arslan Avarisli; Naciye Kabatas; Burcu Kucuk Bicer; Canan Gurdal
Journal:  Int Ophthalmol       Date:  2020-04-24       Impact factor: 2.031

6.  Dry eye syndrome in aromatase inhibitor users.

Authors:  Kiran Turaka; Jennifer M Nottage; Kristin M Hammersmith; Parveen K Nagra; Christopher J Rapuano
Journal:  Clin Exp Ophthalmol       Date:  2012-11-06       Impact factor: 4.207

7.  Dry eye signs and symptoms in aromatase inhibitor treatment and the relationship with pain.

Authors:  Emma Gibson; Fiona Stapleton; Rachel Dear; James S Wolffsohn; Blanka Golebiowski
Journal:  Ocul Surf       Date:  2019-10-24       Impact factor: 5.033

Review 8.  Meibomian Gland Disease: The Role of Gland Dysfunction in Dry Eye Disease.

Authors:  Priyanka Chhadva; Raquel Goldhardt; Anat Galor
Journal:  Ophthalmology       Date:  2017-11       Impact factor: 14.277

Review 9.  Selective estrogen receptor modulators: tissue specificity and clinical utility.

Authors:  Stephen Martinkovich; Darshan Shah; Sonia Lobo Planey; John A Arnott
Journal:  Clin Interv Aging       Date:  2014-08-28       Impact factor: 4.458

Review 10.  Gonadal Hormones and Retinal Disorders: A Review.

Authors:  Raffaele Nuzzi; Simona Scalabrin; Alice Becco; Giancarlo Panzica
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-02       Impact factor: 5.555

View more
  1 in total

1.  The use of androgen deprivation therapy for prostate cancer and its effect on the subsequent dry eye disease: a population-based cohort study.

Authors:  Hsiang-Wen Chien; Chiao-Wen Lin; Chia-Yi Lee; Jing-Yang Huang; Shun-Fa Yang; Kai Wang
Journal:  Int J Med Sci       Date:  2022-06-21       Impact factor: 3.642

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.